IARTHIGH SIGNALFINANCIAL10-K

Integra LifeSciences experienced a dramatic deterioration in operating cash flow alongside a near-complete cessation of share buyback activity, signaling potential operational stress.

The substantial decline in operating cash flow combined with minimal share repurchases suggests management is conserving cash amid operational challenges. The company's reduced financial flexibility is further evidenced by lower stockholders' equity and total assets, indicating potential balance sheet pressures that warrant close monitoring.

Comparing 2026-02-26 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

Integra's financial profile shows concerning cash generation trends with operating cash flow declining substantially while the company pulled back almost entirely from share buybacks. The balance sheet contracted meaningfully with lower total assets and stockholders' equity, though current liabilities also decreased significantly. Despite these pressures, the company continued investing in R&D with a 23% increase, suggesting management remains committed to innovation even as gross profit declined modestly.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-99.6%
$52.5M→$221K

Buyback activity reduced 99.6% — capital being redeployed elsewhere or cash conservation underway.

Operating Cash Flow
Cash Flow
-61.1%
$129.4M→$50.4M

Operating cash flow fell 61.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-50.6%
$922.1M→$456.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Stockholders Equity
Balance Sheet
-32.5%
$1.5B→$1.0B

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
+23%
$63.5M→$78.0M

R&D investment increased 23% — signals commitment to future product development, though near-term margin impact.

Capital Expenditure
Cash Flow
-22%
$104.4M→$81.4M

Capex reduced 22% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Inventory
Balance Sheet
+14.8%
$429.1M→$492.7M

Inventory built 14.8% — monitor whether demand supports this build or if write-downs may follow.

Total Assets
Balance Sheet
-10.8%
$4.0B→$3.6B

Total assets contracted 10.8% — asset sales, write-downs, or balance sheet optimization underway.

Gross Profit
P&L
-10.7%
$952.9M→$851.0M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-25
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 40 Item 7A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 56 Item 13.
BUSINESS OVERVIEW Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives.
We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care.
The CSS segment, which represents approximately 70% of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care, and otolaryngology, commonly referred to as ear, nose, and throat ( ENT ).
Our TT segment generates about 30% of our overall revenue and focuses on wound reconstruction and care and private label.
Each of these categories and the key products sold therein are described in more detail below.
CODMAN SPECIALTY SURGICAL Neurosurgery : In neurosurgery, we are a global leader in neuro-access, neuro-surgical and neuro-monitoring technologies.
Our product portfolio represents a continuum of care from pre-operative, to the neurosurgery operating room, to the neuro-critical care unit and post care for both adult and pediatric patients suffering from brain tumors, brain injury, cerebrospinal fluid pressure complications and other neurological conditions We offer leading technologies in dural repair, ultrasonic tissue ablation, intracranial pressure ( ICP ) monitoring, hydrocephalus management, and cranial stabilization systems, while providing a rich research and development pipeline for growth.
With thousands of surgical instrument products, comprised of a comprehensive portfolio of reusable and disposable instruments, including forceps, retractors, scissors, and curettes, tailored for neurosurgery and spine surgery including specialty surgical instruments, we call on the central sterile processing unit of hospitals and acute care surgical centers.
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 38 Item 7A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matte rs 57 Item 13.
and international governmental, regulatory, fiscal, monetary and public health responses to such crises; and other risk factors described in Item 1A.
BUSINESS OVERVIEW Integra LifeSciences Holdings Corporation was founded in 1989 and is a leading global medical technology company innovating treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, ear, nose, and throat ( ENT ) and regenerative care.
Integra products are sold in more than 120 countries through a direct sales force as well as distributors and wholesalers.
The CSS segment, which represents approximately two-thirds of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care and otolaryngology.
Our TT segment generates about one-third of our overall revenue and focuses on three main areas: complex wound surgery, surgical reconstruction, and peripheral nerve repair.
We source most of our handheld surgical instruments and dural sealant products through specialized third-party vendors.
Vision We aspire to continue to be a worldwide leader in neurosurgery and reconstructive surgery with a portfolio of leading businesses that delivers outstanding customer experiences through innovation, execution and teamwork to positively impact the lives of millions of patients and their families.
Of these five pillars, we have identified three core growth drivers: (1) innovating for outcomes, (2) growing internationally, and (3) broadening our impact on care pathways.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →